

Information Event Pharmaceutical Companies



Livestream Event

25.06.2020



Agenda




- AMVS Organisation
- Status Contracts – Industry and Endusers
- Coding – Summary and frequently asked questions
- Alert Statistics and Actions
- Start Phase Operations
- Outlook on Time period after Start Phase Operations


AMVS Organisation



Austrian Medicines
Verification System



Contractual Relations – Accession- and Service Agreement



Status: 17.06.2020

Operational Fee 2020



Austrian Medicines
Verification System

Fixed Turnover based Part	
Turnover € / User p.a.	Operational Fee € / User p.a.*
<100k	500
100k-3,0 Mio	3 000
3Mio-10 Mio	5 000
10-30 Mio.	15 000
30-50 Mio.	25 000
50-70 Mio.	35 000
70-100 Mio.	45 000
100-150 Mio.	55 000
150-200 Mio.	65 000
200-250 Mio.	75 000
>250 Mio.	85 000

01.12.2019 - 31.01.2020 (as well as any other year):
Submission of turnover-category by form based on past calendar year
Invoiced by end of February latest

Payment due in 30 days

EIGENEINSTUFUNG NUTZER GRUPPE VPU

Basis ist der Nettoumsatz für serialisierungspflichtige Arzneispezialitäten am österreichischen Markt des Vorjahres für die das VPU nach Punkt 3. des Vertrages verantwortlich zeichnet.

Firmenname VPU	
Vertragsnummer des Beitritts- und Nutzungsvertrages	VPU-

Nutzer Gruppen nach Nettoumsatz	Gebühr* € / Nutzer p.a.	
Nutzer Gruppe < 100k	500	<input type="checkbox"/>
Nutzer Gruppe 100k-3 Mio	3 000	<input type="checkbox"/>
Nutzer Gruppe 3-10 Mio	5 000	<input type="checkbox"/>
Nutzer Gruppe 10-30 Mio.	15 000	<input type="checkbox"/>
Nutzer Gruppe 30-50 Mio.	25 000	<input type="checkbox"/>
Nutzer Gruppe 50-70 Mio.	35 000	<input type="checkbox"/>
Nutzer Gruppe 70-100 Mio.	45 000	<input type="checkbox"/>
Nutzer Gruppe 100-150 Mio.	55 000	<input type="checkbox"/>
Nutzer Gruppe 150-200 Mio.	65 000	<input type="checkbox"/>
Nutzer Gruppe 200-250 Mio.	75 000	<input type="checkbox"/>
Nutzer Gruppe > 250 Mio.	85 000	<input type="checkbox"/>

* Der fixe Anteil der Nutzungsgebühr gemäß Punkt 6.1 a) kann sich gemäß Punkt 6.3 ändern. Über die jeweilige Änderung der Anpassung der Nutzungsgebühr informiert die AMVS GmbH in schriftlicher Form (z.B. über Rechnungsaufdruck).

Wir erklären hiermit, dass die oben angeführten Daten richtig und vollständig sind und die vorgenommene Eigenstufung den Nettoumsatz für unsere serialisierungspflichtigen Arzneispezialitäten am österreichischen Markt, entspricht

Ort, Datum

Firmenmäßige Zeichnung
(Firmenstempel, Unterschrift, Name in Druckbuchstaben)

Basis are medicinal products obligated to serialisation in Austria.
*Net in Euro

Operational Fee 2020



Austrian Medicines
Verification System

Variable Volume based Part

Price-Quantity Scale p.a.	€/serial number*
≤ 50.000	0,009
50.001 - 500.000	0,008
500.001 - 2.000.000	0,007
≥ 2.000.001	0,004

Degressiv calculation of the volume based part per year

Basis are the number of uploaded serial numbers into the AMVSystem

*Net in Euro

Key date:

✓ 31. March

30. June

30. September

31. December

Invoice latest by:

30. April

31. July

31. October

31. January


Payment due in 30 days

Behavior RPCs



Austrian Medicines
Verification System


Data related to 82% of RPCs were uploaded so far in 2020



Status: 17.06.2020

■ no Data uploaded in 2020 ■ Data uploaded in 2020

Contractual Relations Endusers - technical connection with AMVSystem



Coding – Summary and Frequently Asked Questions



Version 1.0 published in October 2017

Version 2.0 published in April 2018

Version 3.0 published in March 2019

<https://www.amvs-medicines.at/FileDownload/3473>

<https://www.amvs-medicines.at/FileDownload/3474>

Coding



Usage of the 1D-Bar Code

By Feb. 9th 2019 is the printing of the EAN-13 1D-Barcode not required anymore.

Until further notice the EAN-13 1D-Barcode may retain.

Coding



Single Market Product:

- NTIN is used as Product Code (starting with 0908888...)

Multi Market Product:

- Generally GTIN is used as Product Code
- Use of an NTIN of a different country as Product Code:
 - As long as there are no other country specific numbers used in the 2D Data Matrix Code
 - Data Matrix Code without 5th Element

Coding



Upload of Multi Market Packs:

- Art. 33 Abs. 1 del Reg: The information shall be stored in all national repositories serving the territory of the Member State or Member States where the medicinal product bearing the unique identifier is intended to be placed on the market.
- No upload in repositories where the medicinal product is not placed on the market.
This also applies for centrally authorised products
In particular there is no upload required for packs that are brought to Austria in context of the „Arzneiwareneinfuhrgesetz“ (medicinal products import act)

Coding



Remark regarding Upload of National Codes:

The Austrian „Pharmazentralnummer“ (pharmaceutical central number – PZN) must be uploaded using the EMVS Master Data Elements via the European Hub and stored in the national repository system.

(Field „National Code“ of the Market Specific Master Data Elements for Austria)

- Pharmazentralnummer for Austria, 7-digits (incl. check digit)
- For all Products

Coding



Remark regarding Character Set for Serial Numbers und Batch-ID:

- no usage of Y and Z
- no usage of special characters
(batch-ID alphanumeric)
- usage of capital letters

Coding



Q&As of EU Commission, current version 17 from 09.03.2020

2.23. Question: Are there specific requirements for the characters used in batch and serial numbers?

Answer: No. However, in order to reduce the risk of false alerts due to end-user scanner misconfigurations, manufacturers are strongly encouraged to follow the recommendations below.

Serial and batch numbers should preferably:

- Contain only uppercase letters;
- Not include special characters (eg. hyphens, question marks, etc.); and
- Avoid the use of the letters "I", "O", "Y" and "Z".

Coding



Austrian Medicines
Verification System



Bundesamt für
Sicherheit im
Gesundheitswesen
BASG

Austrian
Federal Office for
Safety in Health Care
BASG

Communication from the Federal Office for Safety in Health Care concerning the obligations of the manufacturers placing safety features pursuant to Delegated Regulation (EU) 2016/161

- Taking into account the observations set out under 2.23 in the Q & A document of the European Commission concerning the particular requirements relating to the characters used in batch IDs and serial numbers.

Coding



Potential wrong inquiries when using special characters

Example: Batch ID A33/01

Wrong Interpretation by Scanner / Software:


A33-01

A33701

A33

Status productive AMVSystem Enduser Transactions and Alerts

Figures per working day without OBP-Alerts




Status productive AMVSystem Enduser-Alerts per Working Day




Austrian Medicines
Verification System

without OBP-Alerts



Weekly Alert Rate in Europe



Alert Rate incl. OBP-Alerts

Actions performed by AMVS




Cause	Affected	Actions
Indian Packs	RPCs	Exception list by 12/2019
Expiry Date Matching	Endusers / RPCs	By Autumn 2020: Match only YYMM
Errors by Data Upload	RPCs	Information Events, Direct Contacting
Scan Configuration	Endusers	Information Events, OnePager, Testscan with Reference Code, Direct Contacting of Endusers and Software Suppliers
Double Decommissionings	Endusers	Information Events, One Pager, Direct Contacting of Endusers
Not / less active Endusers	Endusers	Information Events, Direct Contacting by AMVS and Chambers

Actions performed by AMVS Exception List Indian Packs



Decommissionings of Products on the Exception List



Notification in case of Error-Messages



How do I as RPC/VPU get notifications on error-messages?

- OBP has to be registered for the EMVO-Webservice
- RPC to get in contact with the OBP / the OBPs
- Forwarding of the Austrian error messages to the RPC by the OBP (starting with AT-...)

Current Challenges – Industry



Bundesamt für
Sicherheit im
Gesundheitswesen
BASG

Austrian
Federal Office for
Safety in Health Care
BASG

Communication from the Federal Office for Safety in Health Care concerning the obligations of the manufacturers placing safety features pursuant to Delegated Regulation (EU) 2016/161

- Paying particular attention to checking the completeness of the uploaded data in the repository prior to the first delivery to Verifying and Dispensing Locations.
- Recommendation to perform random checks of the uploaded data for correctness (batch number, expiry date).

Current Challenges – Industry



Error „Serial Number not found“

Reasons:

- Data package of a partial batch has not been uploaded
- Individual serial numbers were segregated at the packaging line but the packs were brought on the market

AMVS cannot distinguish if the serial number is missing in the system or if there is a mismatch in data retrieval.

→ **Monitoring of all alerts and feedback to AMVS by industry**

Current Challenges – Industry



Error „Pack has been decommissioned already “

entire batch decommissioned by OBP:

- destroyed*
- batch recall*
- sale items as free sample

product withdrawn from the market*

→ **Clarification with BASG required on how to proceed with this batch**

Start Phase Operations from 09.02.2020

Endusers shall


- recognize process and handling errors
- optimize implemented processes

Error codes are analyzed but not categorized as potential falsifications.

Affected packs are checked for integrity and authenticity and the verifying or dispensing location decides upon dispensing.

amvs 

Austrian Medicines
Verification System



Start Phase Operations from 09.02.2020



- Delegated regulation since 09.02.2019 in place. Disobedience of relevant duties by endusers, OBP, RPC and MAH will lead to sanctions by the respective competent bodies.
- Ongoing evaluation by representatives of AMVO, AMVS and BASG, first target figures have been met.
- Launching of next implementation steps in autumn 2020.

Start Phase Operations from 09.02.2020



Austrian Medicines
Verification System




Bundesamt für
Sicherheit im
Gesundheitswesen
BASG



Austrian Medicines
Verification Organisation

Start Phase Operations (from 09/02/2020)



<https://amvs-medicines.at/infothek/startphase-echtbetrieb/>

<https://www.amvs-medicines.at/en/infothek/start-phase-operations/>

Process Potential Incident of Falsification after Start Phase

Guidance - Potential / Confirmed Incident of Falsification within the context of Dispensing or Verifying Medicinal Products in Austria


Version 1.0

Published 25.01.2019

June 25th 2020 | AMVS GmbH | Information Event | Livestream Event



Austrian Medicines
Verification System



Start Phase Operations – Time after Start Phase



Bundesamt für
Sicherheit im
Gesundheitswesen
BASG

Austrian
Federal Office for
Safety in Health Care
BASG

Communication from the Federal Office for Safety in Health Care concerning the obligations of the manufacturers placing safety features pursuant to Delegated Regulation (EU) 2016/161

- Proactive cooperation with AMVS upon occurrence of alert messages, especially as regards ruling out technical errors and process errors in accordance with the information regarding the start phase operations.

Start Phase Operations – Time after Start Phase



Duties of Industry

Analysis of all incoming error messages

- Was the affected pack of medicinal product serialised correctly?
- Have pack details been uploaded completely and correctly to the EMVS?
- Is there any process error and/or operator error?

Start Phase Operations

Feedback to AMVS on potential root cause under office@amvs-medicines.at

After the Start Phase

Feedback to BASG and AMVS on potential root cause under serialisierung@basg.gv.at and office@amvs-medicines.at

Process Potential Incident of Falsification after Startphase



Duties of Industry

- Within 3 (three) working days the ruling out of process faults has to be completed and the error corrected (e.g. Upload der fehlenden Daten, Korrektur der fehlerhaften Daten).
- BASG informs the enduser that no incident of falsification is present. BASG has to decide whether the affected pack
 - has to be treated as a case for complaint;
 - will be sampled by BASG;
 - can, in cases the error has been corrected, be released for supply to the public.

Process Potential Incident of Falsification after Startphase




Austrian Medicines Verification System



Bundesamt für Sicherheit im Gesundheitswesen
BASG


Guidance - Potential / Confirmed Incident of Falsification



<https://amvs-medicines.at/infothek/leitlinie-potenzieller-bestaetiger-faelschungsfall/>

<https://www.amvs-medicines.at/en/infothek/guidance-potential-confirmed-incident-of-falsification/>

Questions and Discussion



Thank you for your
participation!



You are always welcome to contact us under
office@amvs-medicines.at or +43 1 9969499 0



Austrian Medicines
Verification System

DISCLAIMER

The material in this presentation has been prepared by AMVS GmbH and is general background information about the FMD project report Austria current as at the date of this presentation. This information is given in summary form and does not purport to be complete.

Any content of this presentation may not be used without prior written permission from AMVS GmbH.

© AMVS – Austrian Medicines Verification System GmbH

Management: Christoph Lendl, MSc.

Square One, Leopold-Ungar-Platz 2, Stiege 1, Top 134, 1190 Vienna, Austria

+43 1 9969499-0

office@amvs-medicines.at; amvs-medicines.at

FN 466094 h; HG Wien; UID: ATU 72357059; DVR Nr.: 4018122